PF-Atlas › Clinical Trials › NCT02606877
A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination
nintedanib · Phase 4
Registry ID
NCT02606877
Phase
Phase 4
Status
Completed
Drug / intervention
nintedanib
Sponsor
Boehringer Ingelheim
Start
2016-04-19
About this trial
nintedanib is evaluated in NCT02606877, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Boehringer Ingelheim. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02606877 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.